Anbio Biotechnology (NASDAQ:NNNN) Short Interest Update

Anbio Biotechnology (NASDAQ:NNNN) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 47,525 shares, an increase of 50.5% from the July 15th total of 31,583 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 38,778 shares, the short-interest ratio is currently 1.2 days.

Anbio Biotechnology Stock Performance

NASDAQ NNNN traded down $0.21 on Tuesday, hitting $8.27. The stock had a trading volume of 51,047 shares, compared to its average volume of 52,796. The firm has a 50-day moving average of $12.06 and a 200-day moving average of $21.04. Anbio Biotechnology has a 52-week low of $7.08 and a 52-week high of $54.50.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Anbio Biotechnology Company Profile

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.